Following a steep sell-off, the stock now trades at a more balanced valuation of roughly 4 times sales as a price-to-sales (P ...

Given the uncertainty around its top-line growth, short-term investors should exercise caution when investing in MRNA stock.

The same day, board member Sagan acquired 31,620 shares, valuing the stock at around $1 million ... next steps pertaining to the case. Moderna, Inc. price | Moderna, Inc. Quote ...

two purchases of Moderna's stock by a firm controlled by MRNA CEO Stephane Bancel were reported. Bancel's company, called Boston Biotech Ventures, bought 102,821 shares for an average price of $31.04.

Moderna granted its chief legal officer $ ... doled out to compensate for the steep decline in the company's stock price following the end of the COVID-19 pandemic. Klinger joined the Cambridge ...

These ratings communicate expectations for the relative performance of Moderna compared to the broader market. Price Targets: Analysts set price targets as an estimate of a stock's future value.

Delving into the details, we found 40% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we ...

Moderna Inc.’s stock tumbled 4% Thursday after a report that health officials are reviewing a contract the company won from the Biden administration to support efforts to develop a bird-flu vaccine.

Moderna’s stock and future vaccine research programs ... and four Sells assigned in the last three months. The average MRNA price target of $42.93 implies a 41.4% upside from current levels.